Advertisement

Topics

Latest "Boehringer Ingelheim Corporation" News Stories - Page: 4

09:37 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 76–100 of 986

Relevant

Sanofi and Boehringer Ingelheim close 
business swap


Albert van Eijk, Director of Oncology, Boehringer Ingelheim

Albert van Eijk, Director of Oncology, Boehringer Ingelheim

Boehringer Ingelheim expands Venture Funds to €250m


Boehringer Ingelheim bags ViraT in €210m deal

Boehringer and Lilly report positive data from Tradjenta trial

Boehringer Ingelheim and Eli Lilly have reported positive results from the CAROLINA cardiovascular outcomes trial of Tradjenta (linagliptin) in type...Read More... The post Boehringer and Lilly report positive data from Tradjenta trial appeared first on Drug Development Technology.

Pharmaxis advancing partnership talks for LOXL2, starting pancreatic cancer program

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips updates Proactive Investors on the pharmaceutical research company’s key programs, including the latest on the anti fibrotic LOXL2 program which should be partnered on next year. A partnership with Boehringer Ingelheim is progressing well, with representatives visiting Australia this week to update on Phase II Clinical Trials in diabetic ...

Boehringer and Domain Therapeutics form CNS drug discovery alliance

Boehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs...Read More... The post Boehringer and Domain Therapeutics form CNS drug discovery alliance appeared first on Pharmaceutical Technology.

Bioharmony, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection

Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the The post Bioharmony, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection appeared first on Pharmaceutical Business review.

Boehringer, Tsinghua University to develop immunological therapies for infectious diseases

Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases. The collaboration brings together The post Boehringer, Tsinghua University to develop immunological therapies for infectious diseases appeared first on Pharma Business review.

Boehringer's France restructure will cull over 300 jobs

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country. The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon. read more

Bioharmony Therapeutics, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection

Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the The post Bioharmony Therapeutics, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection appeared first on Pharmaceutical Business rev...

Boehringer Ingelheim to cut 10 percent of workforce in France: reports https://www.firstwordpharma.com/node/1610513 

Boehringer Ingelheim to cut 10 percent of workforce in France: reports https://www.firstwordpharma.com/node/1610513 

Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase...  

Ny lungbehandling säker

Nytt läkemedel vid idiopatisk lungfibros Boehringer Ingelheim har visats vara säkert.

R&D Deal, PTV News: May 06, 2010

Boehringer Ingelheim and Micromet collaborate on R&D and commercialisation of cancer therapy

Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration http://dlvr.it/QzVs0T pic.twitter.com/SkvR3ist2y

Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration http://dlvr.it/QzVs0T  pic.twitter.com/SkvR3ist2y

Cancer Cell Therapy: Global Start up Acquisitions in Oncolytic Viruses (OV) Therapeutics – a Pipeline of 70 OVs in Clinical Development and another 95 in Preclinical Programs

Cancer Cell Therapy: Global Start up Acquisitions in Oncolytic Viruses (OV) Therapeutics – a Pipeline of 70 OVs in Clinical Development and another 95 in Preclinical Programs   Reporter: Aviva Lev-Ari, PhD, RN   September 2018  Boehringer Ingelheim is buying ViraTherapeutics in $244M deal Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, […]

GlaxoSmithKline nabs Boehringer Ingelheim's Chris Corsico as head of development https://www.firstwordpharma.com/node/1592150  $GSK

GlaxoSmithKline nabs Boehringer Ingelheim's Chris Corsico as head of development https://www.firstwordpharma.com/node/1592150  $GSK

Boehringer Exercises Option on Second Hepatic Disease Target From Research Collaboration with $DRNA https://www.businesswire.com/news/home/20190104005155/en/Boehringer-Ingelheim-Exercises-Option-Hepatic-Disease-Target …

Boehringer Exercises Option on Second Hepatic Disease Target From Research Collaboration with $DRNA https://www.businesswire.com/news/home/20190104005155/en/Boehringer-Ingelheim-Exercises-Option-Hepatic-Disease-Target …

Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer, in a deal worth up to $300 million. read more

GSK Nabs Boehringer Ingelheim's Chief Medical Officer Christopher Corsico http://dlvr.it/QkhqW2 pic.twitter.com/ogordYl1PW

GSK Nabs Boehringer Ingelheim's Chief Medical Officer Christopher Corsico http://dlvr.it/QkhqW2  pic.twitter.com/ogordYl1PW

Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride

CAROLINA is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor. The trial evaluated the cardiovascular safety of Tradjenta (5 mg once daily) compared with The post Boehringer Ingelheim and Lilly announce the CAROLINA cardiovascular outcome trial of Tradjenta met its primary endpoint of non-inferiority compared with glimepiride appeared first on ...

Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development

Programme could lead to new diagnostic solutions for African swine fever Boehringer Ingelheim demonstrates its focus on prevention and innovation yet again Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine ...

#news #biotech Boehringer inks pact with Domain for GPCR neurology drugs

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Boehringer inks pact with Domain for GPCR neurology drugs .French-Canadian biotech Domain Therapeutics has another big pharma partner, signing a deal with Germany’s Boehringer Ingelheim to develop new … Continue reading →

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the...    


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks